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A B S T R A C T
Simulated human intestinal media, have proved to be a useful biopharmaceutics tool as a dissolution media for
predicting in vivo dissolution and pharmacokinetic profile in humans. During drug product development pre-
clinical animal models are also required to assess drug product performance, and there is a need to develop
species specific intestinal media to similarly predict in vivo pharmacokinetic profiles in each preclinical model.
Pigs, are increasingly being used in preclinical drug development, however to date there is a lack of quantitative
information about the composition of porcine gastrointestinal (GI) fluids. As a result, a porcine biorelevant
medium has not yet been developed, which is essential to improve interpretation and forecast of preclinical
results using biorelevant in vitro dissolution studies. GI fluid samples, were collected from landrace pigs, and
characterized. Fasted State Simulated Intestinal Fluid of pigs (FaSSIFp) was developed based on the physiolo-
gical composition of the GI fluids in terms of pH, buffer capacity, osmolality, surface tension, as well as the bile
salt, phospholipid and free fatty acid content. This study demonstrated that FaSSIFp was superior at predicting
the solubility of the six model drugs in porcine intestinal fluids (PIF). A markedly high correlation (r2 0.98) was
observed between the solubility obtained in PIF and FaSSIFp, whereas poor correlation (r2 0.12) was found for
the solubility of the model drugs between human FaSSIF and PIF. This confirms that species specific biorelevant
intestinal media are crucial to provide more accurate predictions of pharmacokinetic studies in preclinical
models. Additionally, the availability of a species specific intestinal medium offers the potential to improve in
vitro-in silico approaches to predict in vivo absorption and to reduce the overall number of animals needed in oral
drug product development testing.
1. Introduction
Operating within the conventional drug product development
paradigm involves initially in vitro screening, preclinical in vivo testing
followed by clinical evaluation in humans. Reliable and bio-predictive
in vitro models are essential as a guide during pharmaceutical devel-
opment of drug products [1]. In order to gain appropriate predictability
with in vitro models, the models often attempt to mimic biopharma-
ceutical conditions found in humans. Various advanced dissolution
media have been established to mimic the human gastrointestinal (GI)
tract, while some of these in vitro models are complex such as the TNO
Gastro-Intestinal Model (TIM) [2] or the biorelevant gastrointestinal
transfer (BioGIT) system [3,4]. Biorelevant media representing the
fasted state conditions in human intestine (Fasted State Simulated In-
testinal Fluid, FaSSIF), or postprandial conditions (Fed State Simulated
Intestinal Fluid, FeSSIF) [5] has been proposed as early as 1998 and
have been revised (FaSSIF- V2, and FeSSIF- V2) [6] and improved for
the third time (FaSSIF- V3) in 2015 [7]. Markopoulos and co-workers,
proposed the concept of categories to classify the level of simulation of
the luminal composition, ranging from Level 0 (only aqueous solution
with adjusted pH) to Level III (including dietary proteins, enzymes and
viscosity effect) [8]. Level II FaSSIF and Level II FeSSIF can provide a
first insight in vitro to mimic human intraluminal conditions and have
been proved useful for the evaluation of solubility of active pharma-
ceutical ingredients and dissolutions performance of oral drug products
[9].
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FaSSIF and FeSSIF are designed to match pH, bile and phospholipid
concentrations in humans, however given the variations between an-
imal and humans in GI conditions, these media are not readily applic-
able to preclinical animal models. In order to make more scientifically
informed decision in species selection, a thorough understanding of
intestinal conditions in each species is required. In addition, species
specific in vitro models are an essential biopharmaceutics tool to guide
preclinical drug development. A species specific in vitro biopharma-
ceutics tool is also in line with the 3 R’s principles of replacement, re-
duction and refinement. Specially, the ‘replacement’ approach may be
considered, and this is where the development of a porcine biorelevant
medium is advantageous. Improvements in the correlation from in vitro
data will help to reduce the number of animals needed and further
support the selection of the most suitable animal model.
Key differences in canine and human intestinal fluid compositions,
lead to the development of a dissolution media simulating the content
of canine GI tract, special designed to improve prediction and inter-
pretation of preclinical results [10]. Additionally, biorelevant media
simulating fasted conditions in rats has been proposed [11]. All bior-
elevant media are designed to simulated species specific properties in
the GI tract, including pH, buffer capacity, osmolality, surface tension
and hydrodynamic conditions. However, to date there is a clear lack of
information about the composition of porcine GI fluids, and in parti-
cular limited quantitative physiochemical evaluation of intestinal bile
and phospholipids, as well as osmolality estimates. Therefore, currently
no porcine biorelevant media exist which limits the potential to me-
chanistically relate in vivo drug absorption profiles, based on preclinical
pharmacokinetic studies in pigs, to in vitro dissolution behaviour. The
use of human biorelevant media for in vitro - in silico approaches in a
preclinical stage, to predict porcine PK profiles, is open to questions.
Therefore, species-specific biorelevant in vitro testing are needed as an
essential tool for integrating in vitro data into in silico models, in a
preclinical setting.
The aim of this study was to characterise the composition of porcine
gastric fluid (PGF) and porcine intestinal fluid (PIF) samples under
fasted state conditions. A comprehensive physiochemical characteriza-
tion of PIFs including concentrations of bile salts, phospholipids and
fatty acids as well as the pH, buffer capacity and osmolality in the
gastric and intestinal contents was conducted with the ultimate aim of
establishing for the first time a porcine biorelevant medium, i.e. porcine
Fasted State Stimulated Intestinal Fluid (FaSSIFp). For the evaluation of
proposed FaSSIFp medium, solubilities of six model drugs with diverse
physiochemical properties, were determined. The reliability of FaSSIFp
versus FaSSIF to predict solubilites in PIFs was also assessed.
2. Materials and methods
2.1. Materials
Lipoid E PC S (Phosphatidylcholine) was obtained from Lipoid
GmbH (Germany), Sodium taurodeoxycholate; Sodium hydroxide
(NaOH) pellets; Chloroform; Sodium chloride (NaCl); Sodium dihy-
drogen phosphate monohydrate; Sodium oleate were purchased from
Sigma Aldrich (Ireland) and sodium taurocholate was ordered from
Thermo Scientific Ltd., Alfa Aesar (UK). Celecoxib, danazol, felodipine,
ketoconazole, dipyridamole, venetoclax was obtained from Kemprotec
Ltd. (UK). Water of HPLC grade was produced using a MilliQ system
(Merck KGaA, Germany). All other chemicals and solvents were of
analytical or high-performance liquid chromatography (HPLC) grade
and were purchased from Sigma-Aldrich (Ireland) and used as received.
2.2. Collection of porcine gastrointestinal samples
Content sample of the stomach and the small intestine for this study
have been collected in previous studies [12]. The study was carried out
under the licence issued by the Health Products Regulatory Authority
(HPRA), Ireland, as directed by the Cruelty to Animals Act, Ireland and
EU Statutory Instruments (Licence number AE19130/P058). Local
University ethical committee approval was obtained. In the fasted state
the final feeding was provided 24 h prior to euthanasia. As part of the
study design, any remaining food was removed 16 h before euthanasia.
All animals were euthanized by intravenous injection of pentobarbital
sodium followed by potassium chloride. The peritoneal cavity was ex-
posed by midline incision and the stomach and small intestine were
isolated. Occluding ligatures were applied to the proximal cardiac
sphincter and distal to the pyloric sphincter as well as at the proximal
and distal ends of the small intestine. Once both ends were secured,
both the stomach and small intestine were removed from the peritoneal
cavity. The luminal contents were collected from the stomach and in-
testine and stored in sterile 50 mL sample tubes. Physiochemical
characteristics were measured immediately upon collection. The pH
was measured using a calibrated Jenway 3510 pH meter. Subsequently,
the samples were frozen (−80 °C) until further analysis.
2.3. Physicochemical parameters of porcine gastric fluid (PGF) and porcine
intestinal fluid (PIF)
2.3.1. pH and buffer capacity
A calibrated pH meter (model 3510, JENWAY) was used for pH
measurements, pH was measured immediately after the collection of
the fresh samples without prior processing.
The buffer capacity was calculated using equation (1):
=β ΔAB/ΔpH (1)
where △ AB is the amount of acid or base added and △ pH is the
change induced by the acid or base added. △ AB and △ pH were
determined by titration of PIF and PGF. The volume of 0.1 N hydro-
chloric acid solution or 0.1 N sodium hydroxide was determined to
change the pH by one unit of PIF and PGF, respectively.
2.3.2. Surface tension
The surface tension was conducted using a Lecomte du Nouy
Tensiometer (Kruess, Germany, model 6.0). The classical ring system
approach (a platinium-iridum ring) was used. Before measurements, the
tensiometer was calibrated with Milli-Q water to 71.5 mN m−1, at
20 °C.
2.3.3. Osmolality
Osmolality was measured by using the freezing point depression
technique (semimicro osmometer Typ Dig L; Knauer, Berlin, Germany).
2.3.4. Phospholipid and bile acid analysis
2.3.4.1. Sample preparation. Gastric and intestinal fluid samples were
diluted 1:1 (V/V) with isotonic phosphate buffered saline pH 7.4 and
then sonicated using a Microson XL 2000 Ultrasonic Cell Disrupter.
Extraction of lipids was performed according to the method of Folch
et al. [13]. In brief, a 10 μL aliquot of each sample was extracted with
3 mL chloroform/methanol (2/1, V/V) and 17:0
lysophosphatidylcholine (Avanti Polar Lipids, Alablaster, AL, USA),
12:0/12:0 phosphatidylcholine (Avanti Polar Lipids), cholesterol-d7
(Avanti Polar Lipids), glycocholic acid-d4 (Cayman Chemicals, Ann
Arbour, MI, USA), cholic acid-d4 (Cayman Chemicals) and
heptadecanoic acid (Sigma-Aldrich, Poole, UK) were added as
internal standards. The mixture was then left to stand on ice for 1 h.
The samples were partitioned by the addition of 750 μL of 0.1 M KCl
and the mixture was centrifuged to facilitate phase separation. The
upper methanolic phase was removed and discarded while the lower
chloroform layer was evaporated to dryness under a gentle stream of
nitrogen gas.
2.3.4.2. Quantification of phospholipids and bile acids. Lipid extracts
were reconstituted in 250 µL methanol containing 5 mM ammonium
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formate (Sigma, Poole, UK) and analysed by liquid chromatography-
mass spectrometry (LC-MS) using a Thermo Exactive Orbitrap mass
spectrometer equipped with a heated electrospray ionization (HESI)
probe and coupled to a Thermo Accela 1250 ultra-high pressure liquid
chromatography (UHPLC) system. Samples (2 µL) were injected on to a
Thermo Hypersil Gold C18 column (2.1 mm × 100 mm, 1.9 μm)
maintained at 50 °C. Mobile phase A consisted of water containing
10 mM ammonium formate and 0.1% (V/V) formic acid. Mobile phase
B consisted of 90:10 isopropanol/acetonitrile containing 10 mM
ammonium formate and 0.1% (V/V) formic acid. The initial
conditions for analysis were 65% A/35% B and the percentage of
mobile phase B was increased from 35% to 65% over 4 min, followed by
65%-100% over 15 min held for 2 min before re-equilibration to the
starting conditions over 6 min. The flow rate was 400 µL/min. Samples
were analysed in positive and negative ion modes over the mass to
charge ratio (m/z) range 250–2000 at a resolution of 100,000. The
signals corresponding to the accurate m/z values for [M + H]+ ions of
lysophopholipids and diacyl phospholipids and [M−H]- ions of
unconjugated and conjugated bile acids were extracted from raw LC-
MS data sets with the mass error set to 5 ppm. Quantification was
achieved by relating the peak area of each lipid species to the relevant
internal standard and the concentrations were normalised to volume.
2.3.4.3. Quantification of free fatty acids and free
cholesterol. Trimethylsilyl (TMS) ethers of free fatty acids and
cholesterol were made by derivatising with 100 µL MSTFA + 1%
TCMS (Fisher Scientific) at 37 °C for 30 min. This mixture was
evaporated and reconstituted in 1 mL hexane. GC–MS analysis was
performed using a Thermo Trace Ultra gas chromatograph fitted with
an Agilent J&W DB-5 ms column (30 m × 0.25 mm i.d. × 0.25 µm
film) and coupled to a Thermo ISQ mass spectrometer. 1 µL was
injected in splitless mode using helium (1 mL/min) as a carrier gas.
After a delay of 2 min at 50 °C, the temperature was ramped to 300 °C at
10 °C/min and then held for 8 min. The mass spectrometer was
operated in full scan mode over the mass range m/z 50–500. The
ionisation energy was 70 eV and the source temperature was 220 °C.
Quantification was achieved by relating the peak area of individual free
fatty acids and cholesterol to the peak area of the relevant internal
standard and the concentrations were normalised to volume.
2.4. Composition of porcine fasted state simulated intestinal fluid
2.4.1. Buffer
A suitable buffer for the porcine simulated biorelevant media was
chosen, based on the pH of the porcine fluids, which were collected
post-mortem. The buffer concentration was calculated according to the





β 2.3C Ka[H O ]




where β is the buffer capacity, C the total buffer concentration (sum of
the molar concentration of acid and salt), Ka is the acid dissociation
constant, [H3O+] is the molar concentration of the hydronium ion.
2.4.2. Osmolality
The amount of sodium chloride, which is needed to adjust the os-
molality of the biorelevant medium to physiological conditions, was
calculated according to Raoult’s law on the basis of the freezing point
depression:
= ∗ ∗ΔT i K mf f (3)
△Tf is the freezing-point depression, i is the van’t Hoff factor, Kf is the
cryoscopic constant (−1.858 K kg mol−1), and m is the concentration
in moles of solute per kilogram of solvent (mol kg−1) or molality of the
solution.
2.4.3. Development of simulated porcine fluids
While chenodeoxycholic and hyodeoxycholate acid are considered
the major bile salts, taurocholate (TC) and taurodeoxycholate (TDC) are
the most widely utilised bile salts in commercially available simulated
intestinal media, and were therefore selected based on commercial
considerations. This also facilitates future applications where species
specific biorelevant media may be prepared with a common set of bile
salts. The ratio of TC: TDC was based on the physiological data of this
study, which showed that 35% belong to primary bile acids (TC) and
65% belongs to secondary bile acid (TDC). Additionally, the phospho-
lipid (PL) to bile ratio was also fixed at 0.013 (total PL/ total bile mM),
as per the pig intestinal fluids. An approach by Arndt and co-workers
was used to determine the representative bile salt concentrations for
TC, TDC and PL [10]. In brief, the solubility of celecoxib, danazol,
ketoconazole, felodipine, dipyridamole and venetoclax was measured
in pig intestinal fluids and in a phosphate buffer (buffer capacity ad-
justed to the measured data in pig intestinal fluids) at pH 7.0 with
varying TC/TDC and PL concentrations (ratios fixed). This resulted in
six drug specific ‘standard bile concentration versus solubility curves’,
which were used to calculate the bile and phospholipid concentrations,
which would match the ex vivo measured solubilites in pig fluids. The
final TC/ TDC and PL concentration for the porcine biorelevant media
was calculated as the mean of TC/ TDC and phospholipid concentra-
tions obtained with all six drugs.
2.4.4. Example of FaSSIFp preparation
(1) Blank buffer is prepared using the buffer salts calculated for one
litre of FaSSIFp medium, containing sodium dihydrogen mono-
phosphate, sodium hydroxide and sodium chloride
(2) The pH is adjusted to pH 7.0 (± 0.05) by using sodium hydroxide
solution (0.1 M).
(3) Approximately 20% of the buffer volume is transferred into a
round-bottom flask.
(4) The required amount of sodium taurocholate and sodium taur-
odeoxycholate is calculated and dissolved in the buffer in the
round-bottom flask under continuous stirring.
(5) The amount of lecithin needed is calculated and added to the bile
salt solution using a freshly prepared solution of lecithin in
chloroform (usually 100 mg/mL). This produces a white/milky
emulsion.
(6) The chloroform is roto evaporated under reduced pressure at 40 °C,
for 30 min. This results in a clear solution, which is examined to
have no distinctive odour of chloroform.
(7) The sodium oleate is mixed into the concentrated bile salt and
phospholipid solution in the round-bottom flask under stirring for
approximately 10 min.
(8) Buffer is added (approximately 40% of the final volume) and mixed
in.
(9) The mixture is returned to a volumetric flask. After a final pH
check, the volume is adjusted.
2.5. Solubility studies
The solubility of celecoxib, danazol, ketoconazole, felodipine, di-
pyridamole and venetoclax was determined. Solubility studies were
carried out by the addition of excess of each drug to the media using a
shake flask method (200 shakes/min) with a shake time of 24 h at
37 °C. Samples were taken at 1 h, 2 h, 4 h, 5 h and 24 h and added to
1.5 mL centrifuge tubes. Samples were centrifuged at 37 °C, at
11,000 rpm for 10 min (Mikro 200 R, Hettich GmbH, Germany). The
supernatant was transferred to a new tube and centrifuged again under
the same conditions. The resultant supernatant was analysed using
HPLC after appropriate dilution with the respective mobile phase. All
samples were run in triplicates.
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(I) Solubility studies pig intestinal fluids (PIF): On the day of the so-
lubility experiment all samples were brought to room temperature.
Fluid samples were pooled by taking 3 mL from each sample to
create the PIF samples.
(II) Solubility in FaSSIFp: The porcine biorelevant media was freshly
prepared on the day of the solubility experiment. Preparation
procedure is outlined below.
2.6. Analysis of drug concentrations by HPLC
The drug concentration in the samples was determined by HPLC.
The Agilent 1260 series HPLC system comprised a binary pump, de-
gasser, temperature controlled autosampler, column oven and diode
array detector. The system was controlled, and the data analysed with
EZChrom Elite version 3.3.2. The analysis method for each drug is
described in Table 1, as previously described [10,14].
2.7. Data analysis
Solubility data are presented as mean and standard deviation and
corresponded solubility from literature sources are presented as mean
values and standard deviations where applicable. In vitro solubility data
were tested for significance (p < 0.05) between PIF and FaSSIFp, using
a two-tailed, independent sample t-test, assuming Gaussian distribution
and equal variance. Correlation were carried out using GraphPad Prism
5. Characterisation results from gastrointestinal porcine fluids are
presented as mean and standard deviations, corresponding literature
data for human and dogs are presented as mean and standard devia-
tions.
3. Results and discussion
3.1. Evaluation of porcine gastrointestinal fluid samples in the fasted state
The buffer capacity, osmolality, pH and surface tension of gastro-
intestinal fluids taken post-mortem from landrace pigs are presented in
Table 2. The total phospholipid and bile salt content is presented in
Table 3.
3.1.1. pH
In the fasted state the pH values varied from 1.7 to 3.4 in the sto-
mach (Fig. 1), with a mean value of 2.2 ± 0.7 (median: 1.9). These
values are similar to reported gastric human data of 1.7–3.3 (median
2.5) under fasted conditions [15], but slightly higher than the fasted pH
values in Yucatan minipigs (0.3–1.7) [16]. The pH in the fasted in-
testinal compartment ranged between 6.3 and 7.9 with a mean pH of
7.0 ± 0.5 (median: 7.0). The observed inter-variability was low in-
dicating a consistent and well buffered pH.
In fasted dogs the pH is known to be higher compared to humans
and pigs, an average pH in the stomach of 6.8 ± 0.2 has been de-
scribed [17]. Dogs are often pre-treated with pentagastrin (6 μg/kg
intramuscular) to decrease gastric pH to 1.7–2.2. Therefore, Arndt and
co-workers established two different type of gastric canine media, one
composed at pH 6.5, and the other at 1.5, to reflect both conditions
[10]. The composition of gastric fluids and especially the pH can have a
significant effect on drug solubility. The observed results in pigs support
the suitability of pigs for matching pH conditions in the human GI tract,
which is particularly relevant in the evaluation of drugs where the so-
lubility is strongly pH dependent.
3.1.2. Buffer capacity, osmolality and surface tension
The buffer capacity of porcine gastric fluids was
6.1 ± 3.5 mmol l−1△pH-1. In the literature, values of
14.3 ± 9.3 mmol l−1△pH-1 are reported for human gastric fluids
[18]. Overall, given the wide intra-variability reported in reported va-
lues for humans, the buffer capacity in pigs determined in this study
was similar to, albeit at the lower end, of the estimated range in humans
[18].
The buffer capacity in porcine intestinal samples was
19.4 ± 2.9 mmol l−1△pH-1, a 3.2- fold increase relative to gastric
fluids. The higher buffering capacity of the intestinal fluids is in line
with observations of low inter-pig variability in intestinal pH (Fig. 1). In
fact, compared to human intestinal fluids, the buffer capacity of the
Table 1
HPLC methods of six model drugs utilized for solubility measurements.
Celecoxib Ketoconazole Dipyridamole Felodipine Danazol Venetoclax
Mobile phase (V/V) Acetonitrile/ H2O
(55:45)a










Flow rate (mL/min) 1.0 0.8 1.0 1.0 1.0 1.0
UV wavelength (nm) 254 232 282 360 286 290
Column I I II II I III
Column temperature (°C) 25 RT 40 RT 20 - 25 40
Ret. time (min) 10.5 8.0 11.3 11.8 10.4 9.4
Run time (min) 15.0 10.0 15.0 15.0 15.0 12.0
Injection volume (μL) 20 50 20 20 50 20
a+0.15 % trimethylamine and was adjusted to pH3 with orthophosphoric acid.
b+0.5 % trifluoroacetic acid.
I: Waters Symmetry C18 (5μm 4.5 x 150 mm).
II Phenomenex Gemini (5μm 4.6 x 150 mm).
III Zorbax Eclipse Plus-C18 (5 μm, 4.6 x 150 mm) with a Zorbax Eclipse Plus-C18 guard column (5 μm, 4.6 mm x 12.5 mm).
Table 2
Overview of buffer capacity, osmolality and surface tension in porcine gastric
and small intestinal fluid samples under fasted conditions (mean±SD) in
comparison to literature data for human gastrointestinal fluids (median, range,
or mean± SD).




Gastric 6.1± 3.5 14.3±9.3a 10.0b







Intestinal 387± 61 197c 69–207c
Surface tension
[mN m-1]




Intestinal 36. 9± 2.6 33.6c 31.1c






Intestinal 6.97±0.53 6.7c 7.1c
7.34± 0.12b
a [18] ; b[10], c[19], d[20], e[21], f[17].
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pig’s intestine is 3.4- fold higher and compared to canine intestinal
fluids, the pig shows a 6.9- fold higher buffer capacity.
The surface tension was 46.5 ± 1.3 mN m−1 in gastric porcine
fluids and 36.9 ± 2.6 mN m−1 in intestinal porcine fluids. A reduction
in surface tension from the stomach to the intestine was expected due to
the bile and phospholipid secretion in the upper small intestine. In
general, the surface tension was lower than the surface tension of water
(72 mN m−1), mainly due to the interfacial surface activity of biliary
lipids. The surface tension of porcine gastro-intestinal fluids was
broadly similar to values previously reported for both humans and
dogs.
The osmolality in intestine fluid samples of landrace pigs was 2-fold
higher compared to reported literature values for human intestinal fluid
samples [19]. However, in gastric fluids of landrace pigs, the de-
termined osmolality of 99.33 ± 53.08 mOsm kg−1 was at the lower
end of reported human data (Table 2).
3.1.3. Phospholipids, cholesterol and fatty acids
The most prevalent phospholipid in the GI tract is phosphati-
dylcholine, which is hydrolysed to lyso-phosphatidylcholine in the
lumen of the small intestine [21]. The total phospholipid amount in the
porcine gastric fluids was 0.20 ± 0.18 mM, which increased to
0.37 ± 0.20 mM in intestinal pig fluids. The lyso-phosphatidylcholine
concentration increased from 0.05 ± 0.05 mM in gastric fluids to
0.27 ± 0.18 mM in intestinal fluids. By comparison, in humans in-
testinal phospholipid concentration are reported to be in the range of
0.01–6.33 [22] and 0.003–2.7 [23]. Therefore, the total phospholipid
concentration in the porcine intestinal fluids is at the lower end of the
range in humans, albeit the variability in reported estimated in humans
is relatively high.
The cholesterol concentrations determined in the porcine gastric
fluids of 0.051 ± 0.060 mM was 28.3- fold lower compared to the
cholesterol concentrations in the intestinal fluids of
1.442 ± 0.772 mM. The higher intestinal cholesterol concentrations
are mainly explainable due to the entero-hepatic-circulation, which not
only recycles bile salts but also cholesterol via the bile juices [24]. The
reported human cholesterol data in the intestine of 1.8 ± 0.21 mM by
Heikkila and co-workers compared well to the intestinal porcine con-
centrations determined in our study [25]. However, Riethorst and co-
workers reported a range of 0.00–0.48 mM (median 0.08 mM) for hu-
mans, which would suggest that intestinal cholesterol concentrations
were possible higher in pigs [22].
The observed total free fatty acid concentration in intestinal pig
fluid was 2.82 mM. A mix of palmitic – (24.68%), stearic – (27.88%),
oleic – (17.76%) and linoleic (29.68%) acids, was determined. In the
intestinal fluids the free fatty acid concentration, which was
2.820 ± 1.633 mM, or approximately 8.2 fold higher compared to the
gastric concentration. While up to 40% of lipid digestion occurs in the
stomach [26], the majority of digestion is occurring in the small in-
testine, which would explain the higher free fatty acid levels in the
intestine. In humans, the free fatty acids are reported to be approxi-
mately 2 mM in intestinal fluids [22], which was similar to the observed
data in landrace pigs.
3.1.4. Bile acid concentration
In total 97.5% of the determined bile acids in intestinal fluids were
conjugated with either glycine 59.3% or taurine 38.2%. Bile acid con-
jugates in porcine gastric fluids showed the same trend with 99.9% of
bile acids conjugated with glycine (96.9%) or taurine (2.9%). The ob-
served data is similar to the estimates described in the literature, that
97.2% of pig bile are conjugated bile acids [27].
The total bile salt concentration in intestinal samples of pigs ranged
from 19.43 to 38.44 mM, which resulted in a mean bile salt con-
centration of 28.33 ± 9.56 mM (median: 27.12 mM) (Table 3). In
general, the mean/median bile salt concentrations in porcine intestinal
fluids was higher than estimates in humans (median 3.30), and the
range of values in pigs was at the higher end of the reported ranges in
humans (range 0.03–36.18 mM) [22]. By comparison, bile salt con-
centrations in canine intestinal fluids (9.39 mM) are generally closer,
albeit on average higher, to estimated medium values in humans [14].
The reason for the high porcine bile salt concentrations are unclear, but
Table 3
Overview of lipid components in porcine gastric and small intestinal fluid samples under fasted conditions (n=3, mean± SD), in comparison to reported data of
human intestinal fluids.
[mM] Landrace pig Human Intestinal Fluids
Gastric Intestinal
Phospholipids total 0.20± 0.18 0.37± 0.20 0.01–6.33, mean 0.95, median 0.58 a
0.003–2.7 (0.32±0.51)b
Lysophospholipids 0.048±0.048 0.27± 0.18 –
Phosphatidylcholine+Sphingomyelin 0.15± 0.13 0.103± 0.024 –
Bile Acids 2.5± 1.7 28.3± 9.6 0.03–36.18, mean 4.16, median 3.30a
2.82d
Cholesterol 0.051±0.060 1.44± 0.77 0.00–0.48, mean 0.07, median 0.08 a
1.8c





Fig. 1. pH values from gastric and intestinal fluid samples of landrace pigs
under fasted conditions, (n = 8); Data is presented as box plot (min. to max,
line median.).
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may reflect species differences. However, it must also be acknowledged
that the sampling technique in the current study was different com-
pared to previous work in humans and dogs. Our studies involved
complete intestinal removal, collection of the entire section of intestinal
fluids, which are then sampled, reflecting a mean sample of intestinal
fluid from the small intestine. In contrast sample are taken by intuba-
tion in humans and dogs, which reflect samples from a specific region in
the small intestine.
In the porcine gastric fluids, a mean bile salt concentration of
2.50 ± 1.73 mM was observed, which was higher than the gastric bile
salt concentration of 0.3 ± 0.3 mM in humans [18]. The high bile
concentrations in the stomach of pigs may indicate some gastro-in-
testinal reflux of bile from the duodenum into the stomach. Alter-
natively, this could reflect a methodological limitation of the current
study during post-mortem sampling. While a ligature was placed be-
tween the stomach and intestine below the pyloric sphincter, we cannot
exclude the possibly of some reflux occurring immediately after eu-
thanasia, given that the ~5 min delay between laparotomy and place-
ment of this ligature. The observed phospholipids/bile acid ratio in
landrace pigs was 0.01 (mM/mM). This was in contrast to reported
phospholipids/ bile acid ratio of 0.30 and 0.25 in humans and pigs,
respectively [24]. In canine intestinal fluids a higher ratio of 0.86 be-
tween phospholipids and bile acids has been reported [14].
Bile acids differ in the number and position as well as the stereo-
chemistry of hydroxyl groups to the steroidal structure. While the im-
pact of bile acid structure is generally not considered in biopharma-
ceutical sense, a recent study showed that drug solubilisation capacity
in bile salt micelles is influenced by the type of bile acid [28]. In par-
ticular, the ratio of primary bile acids (synthesized in the liver) to
secondary bile acids (i.e. primary bile acids that have been en-
zymatically modified by intestinal gut microbiota) was shown to affect
the solubilisation capacity of bile micelles for poorly water soluble
drugs. In general, human and pig individual bile acids differ in their
composition and synthesis [24]. One important difference of bile
composition and synthesis between pigs and humans is the 6α-hydro-
xylation of chenodeoxy cholate to hyocholic acid. In humans hyoco-
holic acid are only present in small amounts [29,30], whereas in pigs it
was one of the key bile acids. While in humans the most common bile
acids are cholic acid, chenodeoxycholic and deoxycholic acid, in pigs
chenodeoxycholic acid (CDC) and hyodeoxycholate acid (HDC) are
described to be one of the major bile acids. The concentration of 11
individual bile salts in the porcine fluids are represented in Table S1
(supplementary data).
The analysis demonstrated that the four dominant bile acids in
fasted intestinal fluids were glycohyodeoxycholic acid (GHDC) 37%,
taurohyodeoxycholic acid (THDC) 24%, glycochenodeoxycholic acid
(GCDC) 19% and taurochenodeoxycholic acid (TCDC) 11% (Fig. 2),
which is in line with porcine bile acid data previously published
[27,31,32]. The dominant bile acids in gastric fluids were broadly in
line with the major intestinal bile acids, albeit minimal taurine con-
jugated were found in the stomach (Fig. 2A). Interestingly, in both
gastric and intestinal fluids the observed ratio of primary: secondary
bile acids were ~1:2.
3.2. Solubility studies in gastric fluid samples
Gastric fluid samples were collected from three male landrace pigs
post-mortem, after an overnight fasting period. For the four model
drugs illustrated in Fig. 3, the solubility was compared to human gastric
fluid (HGF), a biorelevant media simulating the fasted human gastric
conditions (FaSSGF, Level II) and canine gastric fluid (CGF) [10,33,34].
For weakly basic drugs such as ketoconazole the solubility is highly pH
dependent. The ketoconazole solubility observed in PGF was
5756.56 ± 647.69 μg/mL. By comparison to solubilities reported in
HGF was 9025 μg/mL (pH 1.8) and 9054 μg/mL in FaSSGF (pH 1.6)
[34], PGF solubility was 1.5- fold lower to HGF, which can be a result of
the pH difference in pig gastric fluids, as the measured pH in porcine
gastric fluid (PGF) was 2.19 ± 0.67 (Table 1.). The solubility of cel-
ecoxib, danazol and felodipine is pH independent over the physiological
pH range. Celecoxib solubility in PGF was 4.57 ± 1.58 μg/mL, slightly
higher compared to values observed in FaSSGF and CGF [10,33]. The
same trend could also be detected for danazol. In the case of felodipine,
a similar solubility in PGF (1.43 ± 0.08 μg/mL) and FaSSGF (1.40 μg/
mL) was observed, while the solubility in canine gastric fluid was
higher (2.51 ± 0.48 μg/mL) and lower in human gastric fluids
(0.40 μg/mL) [34].
3.3. Development of a biorelevant porcine fasted state simulated intestinal
media (FaSSIFp)
Based on the characterisation of the fasted intestinal porcine fluids a
novel biorelevant media representing the fasted intestinal state in
landrace pigs was developed (FaSSIFp). The pH of the media was set to
7.0 using a phosphate buffer and the buffer salt concentrations were
adjusted to match the experimentally determined buffer capacity of
19 mmol l−1△pH-1. While a range of buffers salts have been used to
simulate intestinal fluids, the most common is phosphate buffers, in-
cluding simulated human and canine intestinal [7]. The phospholipids
were represented by lecithin and used at a ratio of 0.013 (phospholipid
mM/ bile mM) as determined in this study (see section 3.1.4). Based on
previous reports that the ratio of primary: secondary bile salts may
impact solubilisation capacity in simulated intestinal media, the bile
salts were added at a physiological ratio of 35% primary bile acids and
65% secondary bile acids (as discussed in Section 3.1.4). However, due
to limited availability of sufficient quantities of common porcine bile
salts such as taurohyodeoxycholate, glycohyodeoxycholate and gly-
cochenodeoxycholate, sodium taurocholate and sodium taurodeox-
ycholate were used as the primary and secondary bile salts respectively
in FaSSIFp. A high concentration of bile acids seems to influence drug
solubilisation and therefore it appears to be important to take physio-
logical ratios of primary: secondary bile acids into account [28], but at
physiological relevant concentrations it has been hypothesized that the
steroid structure of the bile salts have a negligible impact on the drug
solubilisation, suggesting a flexibility of bile acid selection in prepara-
tion of simulated media [35]. In order to determine the effective con-
centrations of the TC: TDC (35:65) bile salt mixture that achieve similar
overall drug solubilities as porcine intestinal fluids (PIF), the previously
reported method for determined effective bile salt concentrations was
used [10].
For an overall assessment of the impact of selecting TC and TDC
overall, on drug solubility, an indirect approach of solubility mea-
surement was employed using a diverse set of different drugs, i.e. cel-
ecoxib (BCS II), danazol (BCS II), ketoconazole (BCS II), felodipine (BCS
II), dipyridamole (BSC II) and venetoclax (BSC IV). Solubility was
measured ex vivo in porcine intestinal fluids (PIF) and compared to the
solubility in simulated buffers with increasing PL and BS concentra-
tions, while the ratio of PL:TC:TDC (1.3: 34.6: 64.1) remained fixed.
This generated six drug specific ‘standard bile concentration versus
solubility curves’ (Fig. 4). Using this standard calibration curve, the
experimentally determined solubility in PIF was used to work back the
effective concentration of PL:TC:TDC that achieves the same drug
concentration in the simulated media.
The effective concentrations of PL:TC:TDC were similar for five
drugs (celecoxib, danazol, felodipine, dipyridamole and venetoclax).
Ketoconazole showed a higher concentration of PL:TC:TDC, reflecting
the higher inherent solubility in pig intestinal fluids. The final TC, TDC
and PL concentration for the porcine biorelevant media was calculated
as the mean of concentrations obtained with all six drugs. A re-
presentative total bile salt concentration of 14.97 mM (5.25 mM sodium
taurocholate and 9.72 mM sodium taurodeoxycholate) and a total
phospholipid concentration of 0.20 mM was determined using this
approach (Supplementary data, Table S.2). Subsequently, 2.82 mM
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sodium oleate was added to prepare the final media to match con-
centration of free fatty acids determined in this study (see section
3.1.3). Finally, the osmolality was adjusted to 386.67 mOsm kg−1 as
determined in PIF using 134.32 mM sodium chloride. The final media
composition is summarised in Table 4.
3.4. Solubility of six model drugs in porcine gastrointestinal fluids (PIF) and
corresponding porcine biorelevant media (FaSSIFp)
The solubility of six model drugs was determined in FaSSIFp and
compared to the solubilities that were determined in PIF and no sta-
tistically significant difference was observed (Fig. 5). The correlation of
solubility in PIF and FaSSIFp is illustrated in Fig. 6B. The porcine
biorelevant media was able to forecast the solubility in PIF for the
Fig. 2. Percentage of bile acids from porcine gastric (A) and intestinal fluid (B) samples under fasted conditions, (n = 3). Abbreviations: TCDC =
Taurochenodeoxycholic acid; THDC = Taurohyodeoxycholic acid; GCDC = Glycochenodeoxycholic acid; GHDC = Glycohyodeoxycholic acid; THC =
Taurohyocholic acid; GHC = Glycohyocholic acid; CDC = Chenodeoxycholic acid; HDC = Hyodeoxycholic acid; HC = Hyocholic acid; TLCA = Taurolithocholic
acid; GLCA = Glycolithocholic.
Fig. 3. Solubility of felodipine, danazol, celecoxib and ketoconazole in pig gastric fluids (PGF), compared to reported values, in human gastric fluid (HGF), canine
gastric fluid (CGF) and human Fasted State Simulated Gastric Fluid (FaSSGF), [10,33,34]; data is presented as mean± SD, n = 3.
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chosen model drugs with good accuracy. Celecoxib, a weak acid, had a
solubility in PIF (34.5 ± 4.85 μg/mL) that matched the solubility in
FaSSIFp (36.3 ± 4.3 μg/mL). Also, for the neutral compound felodi-
pine had a solubility in PIF (48.2 ± 9.2 μg/mL), which was similar to
FaSSIFp (64 ± 18 μg/mL). In the case of the neutral compound da-
nazol, the solubility in PIF of 13.2 ± 2.4 μg/mL was slightly over-
estimated in FaSSIFp with a solubility of 19.34 ± 0.96 μg/mL. The
solubility of weak bases, such as ketoconazole, dipyridamole and ve-
netoclax is highly dependent on the pH with the general trend of higher
solubility at lower pHs. Venetoclax had a solubility of 163 ± 43 μg/mL
in PIF, which was similar to FaSSIFp (154 ± 15 μg/mL) and also the
solubility of dipyridamole in PIF (266 ± 41 μg/mL) correlated well
with the solubility in FaSSIFp (272 ± 19 μg/mL), albeit showing a
higher variability. Ketoconazole had a solubility of 91.7 ± 4.2 μg/mL
in PIF, while the solubility in FaSSIFp was slightly lower (71 ± 13 μg/
mL). Overall, despite slight variations, FaSSIFp was well able to capture
drug specific high or low solubility resulting in a correlation of r2
0.9825.
While the overall bile salt and lecithin concentrations in the final
assembled FaSSIFp were lower compared to concentration determined
quantitatively in section 3.1.4 (~28 mM), for practical and availability
considerations it was not feasible to use the full range of porcine bile
acids. However, our approach is physiologically relevant in the context
of applying a fixed ratio of primary: secondary bile acids as well as
Fig. 4. Total phospholipid and bile salt concentration versus solubility standard curves for six drugs. Estimation of effective bile salt (BS) and phospholipid (PL)
concentration in porcine intestinal fluid (PIF). BS concentration is represented by sodium taurocholate (TC) and sodium taurodeoxycholate (TDC) and PL con-
centration is represented by lecithin, at a fixed ratio of 1.3:34.6:64.1 (PL:TC:TDC); A: Celecoxib; B: Danazol; C: Felodipine; D: Ketoconazole, E: Dipyridamole; F:
Venetoclax.
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matching the bile acid: phospholipid ratio determined for pig intestinal
fluids. In addition, it should be noted that the use of the measured PIF
total bile and phospholipid concentrations of approximately 28 mM and
0.374 mM, respectively, would overestimated the in vivo solubility of
the drugs (based on the standard bile concentration versus solubility
curves in section 3.3). The effective bile salt and phospholipid con-
centrations of 14.97 mM and 0.20 mM for the composition of FaSSIFp
resulted in a good overall correlation, which supports the feasibility of
the applied development approach.
3.5. Comparison of the measured solubility in porcine intestinal fluids to
human biorelevant media
FaSSIFp contains phospholipids and bile salts at the physiological
ratio of 0.013 (mM/mM) with an effective bile acid concentration of
14.97 mM (5.25 mM sodium taurocholate and 9.72 mM sodium taur-
odeoxycholate) and a phospholipid concentration of 0.20 mM (le-
cithin). In comparison to FaSSIF, which has a taurocholate concentra-
tion of 3 mM and a phospholipid concentration of 0.75 mM, FaSSIFp
shows a 5.0-fold higher bile salt and a 3.8-fold lower phospholipid
content. In comparison to FaSSIF-V2, where the phospholipid content
had been changed to 0.2 mM, FaSSIFp still demonstrates a 5.0-fold
higher bile salt concentration but an identical phospholipid con-
centration. FaSSIF-V3, which has a bile salt concentration (taurocholate
and glycocholate) of 2.8 mM and a phospholipid concentration of
0.07 mM, FaSSIFp shows a 5.3-fold higher bile salt and a 2.9-fold higher
phospholipid content.
It has been reported that the amount of lecithin displays a sig-
nificant role in estimations of in vivo solubility, especially for neutral
drugs [35]. Therefore, in many cases FaSSIF overestimated drug solu-
bilites of neutral compounds when compared to human intestinal fluids
(HIF). In FaSSIF-V2, this was corrected by reducing the phospholipid
content, which seemed more appropriate for reliable solubility esti-
mations [35]. For example, in the case of the highly lipophilic (logP
3.56) BCS class II drug felodipine [34], the solubility in FaSSIF
(47.6 ± 1.1 μg/mL) [10] overestimated the solubility in HIF
(14.00 μg/mL) [35,36]. When compared to PIF (48.25 ± 9.25 μg/mL)
the solubility of felodipine in FaSSIF was similar and in fact due to the
high variability also similar to the felodipine solubility in FaSSIFp
(63.64 ± 17.80 μg/mL). For another model drug celecoxib, FaSSIF
solubility (46.2 ± 0.03 μg/mL) [10] was even higher when compared
to PIF (34.46 ± 4.81 mg/mL). In this case, using FaSSIF would have
overestimated in vivo solubility for celecoxib, while FaSSIFp showed a
similar solubility (36.29 ± 4.28 mg/mL) when compared to PIF. In-
terestingly, in the case of the highly lipophilic (logP 4.53) drug danazol,
FaSSIFp slightly overestimated the solubility in PIF (13.19 ± 2.36 μg/
mL), nevertheless FaSSIFp would capture the trend towards a higher
solubility more accurately than human FaSSIF. Clarysse and co-workers
reported that FaSSIF underestimated the solubility (5.4 ± 0.3 μg/mL)
compared to HIF (reported range: 2.04 ± 1.5 up to 13.2 ± 14.1 μg/
mL) [35–41]. In general, for neutral compounds the developed porcine
media (FaSSIFp) showed the capability to predict the solubility in PIF,
and displayed an advantage over the commonly used human bior-
elevant media in predicting in vivo conditions in pigs (Fig. 6). Fur-
thermore, this study confirms that using human biorelevant media in
estimating in vivo solubility in pigs is not reliable given the overall poor
level of correlation r2 = 0.12.
Weak bases display higher solubility at acidic pH, due to their io-
nization characteristics. Upon oral administration in the fasted state,
concentration gained in the gastric compartment, can exceed solubility
in the contents of the intestinal lumen, and precipitation in the in-
testinal lumen may occur [10]. In the case of the weak base dipyr-
idamole, solubility values in PIF showed high variability (range:
240–313 μg/mL) and an approximately 9-fold higher solubility com-
pared to HIF. While such high variability has not been reported in HIF
solubility studies of dipyridamole (29 ± 0.4 μg/mL) [35], large
variability has also been reported in canine intestinal fluids (range:
25–95 μg/mL,) where it was suggested to reflect fluctuations in bile
concentrations in intestinal fluids [10,14]. In comparison to HIF and
PIF, FaSSIF (19 ± 0.4 μg/mL) underestimated dipyridamole solubility,
while FaSSIFp (272 ± 19 μg/mL) matched the solubility of PIF. Si-
milar results were obtained for the weak base venetoclax. While the PIF
(163 ± 43 μg/mL) and FaSSIFp (153.97 ± 15.08 μg/mL) solubilites
were similar, the solubilites measured in FaSSIF (5.2 ± 0.1 μg/mL)
under predicted the scenario in pig intestinal fluids showing a 30-fold
lower solubility. In the case of the weak base ketoconazole, solubility in
PIF 91.7 ± 4.2 μg/mL was in the range of reported solubility values in
HIF. Multiple independent studies reported the solubility of ketocona-
zole in HIF, obtained results ranged from 28.8 ± 3.0 μg/mL up to
326 ± 366 μg/mL [19,36,39–41]. However, FaSSIF (26 ± 5.2 μg/
mL) underestimated the solubility in PIF, as the solubility in PIF was
3.5- fold higher [40]. In general, also in the case of weak bases FaSSIFp
demonstrated a superior predictability of in vivo solubilities in PIF
compared to the human media FaSSIF.
In summary, for all six model drugs, the use of FaSSIFp resulted in a
better correlation to the PIF solubility than the values reported with
FaSSIF (Fig. 6). While drug solubilites in HIF have been extensively
investigated and reviewed [42], this study provided a first insight into
PIF drug solubilities using 6 model drugs. A limitation of the current
proposed porcine media is that this was designed based on the landrace
pig model, and while there are general similarities across the various
species of pigs [27], inter-species differences may lead to different in-
testinal conditions and potentially limit reliability of the FaSSIFp for
Table 4
Composition and physiochemical properties of Fasted State Simulated Intestinal
Fluid porcine (FaSSIFp).
Composition FaSSIFp mM











Fatty acid Sodium oleate 2.82
pH 7.0
Buffer capacity [mmol l-1△pH-1] 19.4
Osmolality [mOsm kg-1] 387
Fig. 5. Comparison of the solubility of six model drugs in pig intestinal fluids
(PIF) (white bars), and in porcine Fasted State Simulated Intestinal Fluid
(FaSSIFp) (black bars), data is presented as mean± SD, n = 3.
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other species. Nevertheless, landrace pigs have been widely used for
preclinical evaluations [12,43–45], and therefore FaSSIFp specially
designed on landrace pig model, provide a useful in vitro tool. Last it
should be considered that FaSSIFp contains taurocholate (TC) and
taurodeoxycholate (TDC) as bile acids, which is distinctly different to
the variety of determined pig bile components in this study. The use of a
highly complex media may offer a more precise simulated media. While
quantitatively observed total bile acid concentration ranged between
19.43 and 38.44 mM, an effective bile acid concentration of 14.97 mM
(5.25 mM sodium taurocholate and 9.72 mM sodium taurodeox-
ycholate) in FaSSIFp was used to estimate the in vivo solubility. While
this latter approach suggested that the working concentration of TC and
TDC is was lower than the total sum of the range of individual bile salts
determined by mass spectrometry in PIF, we believe that this approach
was more accurate in terms of predicting drug solubility in the pig in-
testine and as a tool for modelling drug absorption in vivo. However,
there are also applications where the absolute concentration of bile salts
reported in Table 3 may be more applicable such as specific input
parameters for PBPK modelling, to utilize and integrate intestinal bile
porcine concentrations into the applied absorption model. Never-
theless, FaSSIFp was markedly superior in predicting the solubility of
the model drugs in pig intestinal fluids compared to human biorelevant
media.
The key impact of this study is that by integrating species specific in
vitro testing with in silico PBPK modelling, more reliable insights can be
achieved in preclinical pharmacokinetic studies to assess the impact of
drug formulation in vivo [46]. As an example, Walsh and co-workers
emphasised that using the canine fasted simulated intestinal media,
resulted in a better predictability of the plasma concentration profiles in
dogs [46]. In comparison human intestinal media was assessed, with
the result that FaSSIF significantly under predicted the observed ab-
sorption in dogs due to a lower solubility. Improvements of biorelevant
media based on species-specific findings will further enhance the cor-
relation, interpretation and extrapolation from in vitro data and can be
employed to allow drug formulation characterisation in advance of in
vivo preclinical testing. Based on the correlations of in vivo solubility in
PIF and the capability of FaSSIFp to estimate the in vivo solubility, the
established porcine biorelevant media seems to be a promising tool for
predicting in vivo performance of oral dosage forms in pigs.
4. Conclusion
In summary, by comprehensively characterising the GI fluids in
landrace pigs, including lipid composition, pH, buffer capacity, os-
molality and surface tension, this study established the basis for a de-
signing a media that simulated intestinal conditions in fasted pigs. The
final FaSSIFp was designed to mimic PIF by matching both the BS:PL
and primary: secondary ratio found in porcine GI fluids. The solubility
of drugs in porcine simulated media were highly correlated (r2 0.98) to
solubility obtained in PIF, whereas poor correlation (r2 0.12) was ob-
tained using human simulated fluids. Therefore, the resulting porcine
biorelevant media, specially designed for pigs used in pharmacokinetic
studies, can be a useful tool in predicting in vivo performance early in
preclinical studies of drugs. Porcine biorelevant media can be re-
commended to achieve more accurate predictions and interpretation of
pharmacokinetic studies after oral administration of new drug candi-
dates.
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